Amgen Buys Cancer Drug.Amgen Inc., the world's largest biotechnology company, agreed to buy Immunomedics Inc.'s epratuzumab Epratuzumab is a humanized monoclonal antibody. Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as lupus (SLE). See also
, an experimental antibody treatment for non-Hodgkin's lymphoma non-Hodg·kin's lymphoma n. Any of various malignant lymphomas characterized by the absence of Reed-Sternberg cells. Non-Hodgkin's lymphoma , to build up its pipeline of cancer drugs. Thousand Oaks-based Amgen will pay Immunomedics, which develops cancer treatments, $18 million plus royalties and clinical-research milestone payments potentially worth $65 million. Amgen also will make one-time one-time adj. 1. or one·time a. Occurring or undertaken only once: a one-time winner in 1995. b. milestone payments totaling up to $225 million if the drug has sales of as much as $1 billion. Amgen will also pay Immunomedics for each second-generation product Amgen develops that is based on epratuzumab. Epratuzumab is being studied in patients who don't respond to Rituxan Ri·tux·an A trademark for the drug rituximab. rituximab Warning - Hazardous drug! MabThera (UK), Rituxan Pharmacologic class: , the current antibody for non-Hodgkin's lymphoma. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion